CorMedix (NASDAQ:CRMD – Get Free Report) and Levitee Labs (OTCMKTS:LVTTF – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
Earnings & Valuation
This table compares CorMedix and Levitee Labs”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CorMedix | $311.71 million | 2.13 | $163.05 million | $2.14 | 3.98 |
| Levitee Labs | N/A | N/A | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for CorMedix and Levitee Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CorMedix | 0 | 2 | 6 | 0 | 2.75 |
| Levitee Labs | 0 | 0 | 0 | 0 | 0.00 |
CorMedix presently has a consensus target price of $15.00, indicating a potential upside of 76.06%. Given CorMedix’s stronger consensus rating and higher probable upside, research analysts clearly believe CorMedix is more favorable than Levitee Labs.
Insider and Institutional Ownership
34.2% of CorMedix shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares CorMedix and Levitee Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CorMedix | 40.49% | 40.52% | 20.61% |
| Levitee Labs | N/A | N/A | N/A |
Summary
CorMedix beats Levitee Labs on 9 of the 9 factors compared between the two stocks.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
About Levitee Labs
Levitee Labs Inc., a multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments, Medical Services and Selling Products. It offers treatments and medications for substance use disorders and chronic pain, such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome, as well as hepatitis-C and mental health conditions. The company operates five clinics under the Levitee Clinics name; and three pharmacies in Alberta under the Levitee Pharmacies name. In addition, it offers electronic-prescriptions in the addiction treatment space under the BlockMD name; and wholesales supplements and superfood under the Earth Circle Organics name. The company was formerly known as Fibonacci Capital Corp. and changed its name to Levitee Labs Inc. in November 30, 2020. Levitee Labs Inc. was incorporated in 2019 and is based in Vancouver, Canada.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
